Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24

作者：

Vogel, AM

Lennon, DR

Broadbent, R

Byrnes, CA

Grimwood, K

Mildenhall, L

Richardson, V

Rowley, S

机构：

[1] Univ Auckland, Wellington, New Zealand

[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand

[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand

[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand

来源：

JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期

关键词：

consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;

D O I：

10.1046/j.1440-1754.2002.00057.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

引用

页码：550 / 554

页数：5

共 50 条

[41] Current respiratory syncytial virus prevention strategies in high-risk infants
Weisman, LE
PEDIATRICS INTERNATIONAL, 2002, 44 (05) : 475 - 480
[42] The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
Speer, Michael E.
Good, Amy B.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 459 - 469
[43] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Sanchez-Luna, M.
Burgos-Pol, R.
Oyaguez, I.
Figueras-Aloy, J.
Sanchez-Solis, M.
Martinon-Torres, F.
Carbonell-Estrany, X.
BMC INFECTIOUS DISEASES, 2017, 17
[44] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
M. Sanchez-Luna
R. Burgos-Pol
I. Oyagüez
J. Figueras-Aloy
M. Sánchez-Solís
F. Martinón-Torres
X. Carbonell-Estrany
BMC Infectious Diseases, 17
[45] Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients
Chavez-Bueno, Susana
Mejias, Asuncion
Merryman, Ruth A.
Ahmad, Naveed
Jafri, Hasan S.
Ramilo, Octavio
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (12) : 1089 - 1093
[46] Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland
Groves, H. E.
Jenkins, L.
Macfarlane, M.
Reid, A.
Lynn, F.
Shields, M. D.
PEDIATRIC PULMONOLOGY, 2016, 51 (04) : 379 - 385
[47] Risk factors for severe respiratory syncytial virus infection in infants
Aujard, Y
Fauroux, B
RESPIRATORY MEDICINE, 2002, 96 : S9 - S14
[48] Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma
Igde, Mahir
Kabasakal, Hilal
Ozturk, Onur
Karatekin, Guner
Aygun, Canan
MINERVA PEDIATRICA, 2018, 70 (03) : 252 - 259
[49] Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
Checchia, Paul A.
Nalysnyk, Luba
Fernandes, Ancilla W.
Mahadevia, Parthiv J.
Xu, Yingxin
Fahrbach, Kyle
Welliver, Robert C., Sr.
PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (05) : 580 - 588
[50] Palivizumab prophylaxis for respiratory syncytial virus in Canada:: utilization and outcomes
Oh, PI
Lanctôt, KL
Yoon, A
Lee, DSC
Paes, BA
Simmons, BS
Parison, D
Manzi, P
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 512 - 518

← 1 2 3 4 5 →